Clinical-scale elutriation as a means of enriching antigen-presenting cells and manipulating alloreactivity

Background aims Clinical-scale elutriation using the Elutra© has been shown to enrich monocytes reliably for immunotherapy protocols. Until now, a detailed assessment of the four (F1–F4) non-monocyte fractions derived from this process has not been performed. Methods Using fluorescence-activated cel...

Full description

Saved in:
Bibliographic Details
Published inCytotherapy (Oxford, England) Vol. 11; no. 2; pp. 218 - 228
Main Authors Micklethwaite, Kenneth P, Garvin, Frances M, Kariotis, Melina R, Yee, Leng L, Hansen, Anna M, Antonenas, Vicki, Sartor, Mary M, Turtle, Cameron J, Gottlieb, David J
Format Journal Article
LanguageEnglish
Published England Elsevier Inc 2009
Informa UK Ltd
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background aims Clinical-scale elutriation using the Elutra© has been shown to enrich monocytes reliably for immunotherapy protocols. Until now, a detailed assessment of the four (F1–F4) non-monocyte fractions derived from this process has not been performed. Methods Using fluorescence-activated cell sorting (FACS), we performed phenotypic analyses to investigate the possible enrichment of T, B, natural killer (NK) and dendritic cells (DC) or their subsets in one or more Elutra fractions. Results Blood DC were enriched up to 10-fold in some fractions (F3 and F4) compared with the pre-elutriation apheresis product. This increased the number of DC that could be isolated from a given cell number by immunomagnetic separation. It was also found that CD62L− effector memory CD4+ T cells were enriched in later fractions. In four of five cases tested, cells from F3 demonstrated decreased alloreactive proliferation in a mixed lymphocyte reaction compared with cells from the apheresis product. B cells were enriched in F1 compared with the apheresis product. Conclusions In addition to providing enrichment of monocytes for the generation of DC, the Elutra enriches cell subsets that may be incorporated into and enhance existing immunotherapy and stem cell transplantation protocols.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1465-3249
1477-2566
DOI:10.1080/14653240802702160